ImmunityBio, Inc. conducted its full year 2025 earnings conference call on March 3, 2026, at 4:30 PM EST. The call featured company leaders and analysts, with a standard disclaimer on forward-looking statements. A replay is available on the company's investor relations website.
ImmunityBio, Inc. (IBRX), a biotechnology firm, hosted its Q4 2025 earnings conference call on March 3, 2026, starting at 4:30 PM EST. The event was led by Dr. Patrick Soon-Shiong, the company's Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, alongside Richard Adcock, President and Chief Executive Officer.
Analysts from several firms joined the call, including Edward Tenthoff from Piper Sandler & Co., Andres Maldonado from H.C. Wainwright & Co., LLC, Jeet Mukherjee from BTIG, LLC, Yuxi Dong from Jefferies LLC, and Jason Kolbert from D. Boral Capital LLC.
The operator opened the session with standard instructions for participants and noted that the call was being recorded. A replay would be accessible in the Investor Relations section of ImmunityBio's website.
As is customary, the company issued a reminder about forward-looking statements under the Private Securities Litigation Reform Act of 1995. These include projections on financial performance, revenues, expenses, cash runway, clinical plans, regulatory approvals, collaborations, manufacturing, commercial launches, market opportunities, and strategy. The statements carry risks and uncertainties that could lead to results differing from expectations. Listeners were directed to the company's most recent SEC filings, specifically the Form 10-K submitted on February 23, 2026, for risk factor details. ImmunityBio advised against over-relying on these statements, which are current only as of the call date, and confirmed no forward financial guidance would be given.
The call transitioned to remarks from Dr. Soon-Shiong and Mr. Adcock, though specific discussion details were not included in the available transcript excerpt.